Nov 08,2019

Mitch Weaver joins Tula’s team as Chief Product Officer

As Tula’s Chief Product Officer, Mitch Weaver has lead the charge taking Tula’s prototype solution and commercializing it for the market. Mitch has held executive technology leadership roles at Hewlett-Packard, Mentor Graphics, Translogic Technology, Cadence Design Systems, Avid Technologies and Symbotic LLC.

View Analyst & Ambassador Comments
Go to original news
Nov 08,2019

Tandem Diabetes Care Announces Upcoming Conference Presentations

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will be attending the following upcoming investor conferences: Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 in Scottsdale; Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 in New York City; and Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 in New York City.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 10,2019

Wellthy Therapeutics launches digital therapeutics in diabetes, cardiovascular conditions in Hindi, Kannada

Wellthy Therapeutics recently announced the launch of its digital therapeutics in diabetes and cardiovascular conditions in Hindi and Kannada, furthering its effort towards effective disease management for more than 528 million Hindi speakers and more than 43 million native Kannada speakers in India.

PRODUCT

#dtx

View Analyst & Ambassador Comments
Go to original news
Nov 11,2019

Veterans Living with Type 2 Diabetes Achieve Rapid Health Improvements in Virta Health Partnership with VA

Data from the pilot conducted by Virta Health with the U.S. Department of Veterans Affairs (VA) shows that 84% of veteran patients on the Virta Treatment for 90 days achieved glycemic outcomes below the diabetes threshold or at least a one-point drop in HbA1c (a measure of blood sugar).

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Nov 11,2019

Nemaura Medical Reports Results and Provides Business Update for the Second Quarter Ended September 30, 2019

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the second quarter ended September 30, 2019.

View Analyst & Ambassador Comments
Go to original news
Nov 12,2019

Medicare Establishes National Payment Rate for Eversense® CGM System

Senseonics announced today that the Centers for Medicare and Medicaid Services (CMS) finalized a national payment rate for Eversense that was recently published in the calendar year 2020 Physician Fee Schedule Final Rule. The Eversense CGM system will be the first CGM technology to be reimbursed through the Part B Medical Services benefit for Medicare beneficiaries and expands access to the latest innovation in continuous glucose monitoring.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 12,2019

Senseonics Holdings, Inc. Reports Third Quarter 2019 Financial Results

In the third quarter of 2019, total revenue, net was $4.3 million, which includes U.S. net revenue of $0.5 million after accounting for gross to net reductions, primarily related to the Eversense Bridge Program and OUS net revenue of $3.8 million, compared to total revenue, net of $5.2 million for the third quarter of 2018.

View Analyst & Ambassador Comments
Go to original news
Nov 12,2019

Action Urgent Care Selects MyDario

Global digital therapeutics innovation leader, DarioHealth Corp. announced today the launch of a Dario-powered digital diabetes program with Action Urgent Care. Action Urgent Care has experienced rapid growth since its first clinic opened in San Jose in 2013, to more than 40 points of care they operate throughout California today. Some clinics have their own premises, while others are located inside Safeway and Vons supermarkets. Action Urgent Care will now offer MyDario™ as an additional application within its mobile platform.

COLLABORATION PARTNERSHIP

#institution

#mobile app

#dtx

View Analyst & Ambassador Comments
Go to original news
Nov 13,2019

ABBOTT ANNOUNCES ROBERT B. FORD TO SUCCEED MILES D. WHITE AS CHIEF EXECUTIVE OFFICER ON MARCH 31, 2020

The Board has unanimously appointed Robert B. Ford, a 23-year Abbott veteran, to succeed Mr. White as CEO. Mr. Ford currently serves as President and Chief Operating Officer and has been elected to the Board.

View Analyst & Ambassador Comments
Go to original news
Nov 14,2019

BD to Present at Jefferies 2019 London Healthcare Conference

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019, at 6:20 a.m. ET..

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES